Madryn Asset Management

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Calibrate Health, Inc., established in 2020 and based in New York, specializes in digital metabolic health services for sustainable weight loss. The company combines FDA-approved metabolic medications with a comprehensive curriculum and personalized virtual coaching to address the root causes of weight issues and promote long-term behavior change. Calibrate's approach, led by experts in obesity and nutrition science, aims to improve metabolic health and drive lasting results.

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Founded in 2015, Alto Pharmacy is America's leading digital pharmacy, transforming the $500 billion pharmaceutical industry. It combines expert pharmacist care with purpose-built technology to deliver a more convenient and affordable medication experience for customers. With over three million prescriptions fulfilled and expansion into twelve markets, Alto offers medication management and scheduled delivery through its mobile app, boasting an industry-leading NPS score of 86.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Dialyze Direct is a healthcare company that specializes in providing staff-assisted home hemodialysis services for elderly patients suffering from End Stage Renal Disease. The company focuses on delivering customized and coordinated dialysis care through a team of registered nurses, dieticians, and social workers. By offering these services in a home setting, Dialyze Direct aims to improve patient outcomes while reducing overall healthcare costs. The approach not only alleviates the need for transportation but also helps minimize hospital readmissions, thereby enhancing the quality of life for geriatric patients.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Aquestive Therapeutics is a specialty pharmaceutical company dedicated to developing and commercializing innovative products to address unmet medical needs, with a focus on diseases of the Central Nervous System (CNS) and severe allergic reactions. Its portfolio includes marketed products like Suboxone, Emylif, Ondif, and Sympazan, along with pipeline candidates such as Libervant Buccal Film and AQST-108.

Veran Medical Technologies is an image-guided medical device company that develops minimally invasive tools for interventional oncology and pulmonology. Its products enable physicians to diagnose cancer earlier and deliver targeted therapies through navigation and real-time visualization. The portfolio includes SPiNView thoracic navigation system, SPiNPerc, SPiN Drive System, vPad2, and vTrack 2.0 instruments to guide biopsies and other procedures in the lungs, as well as ig4 IR System, an electromagnetic navigation platform that supports biopsies, drainages, and ablations in the lungs, liver, and kidneys. The IG4 Platform integrates CT data with respiration, contrast-enhanced structures, PET, and ultrasound to provide a dynamic, three-dimensional airway roadmap during procedures. Veran is based in St. Louis, Missouri.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Establishment Labs designs, develops, manufactures, and markets silicone-filled breast and body shaping implants worldwide. It offers a range of implant options and provides Q Inside Safety Technology for non-invasive data access. The company also operates a consultation center and offers MotivaImagine application and external sizing system. Its products are sold through exclusive distributors and direct sales force in over 80 countries.

BioQ Pharma Incorporated is a specialty pharmaceutical company that develops and commercializes a range of ready-to-use infusible pharmaceuticals, focusing on post-surgical pain management, anesthesia, and sedation. The company offers products such as Ropivacaine for pain relief and Propofol for anesthesia, while also working on pipeline candidates in antibiotics and oncology. BioQ Pharma utilizes a proprietary unit-dose infusion system designed to enhance the efficiency, safety, and sterility of medication administration at the point of care. This innovative approach aims to address critical issues in infusion therapy, including medication errors and cost-effectiveness, ultimately improving patient quality of life. The company markets its products through partnerships in the U.S., Europe, China, and Taiwan, collaborating with notable firms in the pharmaceutical industry. Established in 2003 and based in San Francisco with an additional site in Gent, Belgium, BioQ Pharma was formerly known as BioQuiddity Incorporated until its name change in 2015.

BioQ Pharma Incorporated is a specialty pharmaceutical company that develops and commercializes a range of ready-to-use infusible pharmaceuticals, focusing on post-surgical pain management, anesthesia, and sedation. The company offers products such as Ropivacaine for pain relief and Propofol for anesthesia, while also working on pipeline candidates in antibiotics and oncology. BioQ Pharma utilizes a proprietary unit-dose infusion system designed to enhance the efficiency, safety, and sterility of medication administration at the point of care. This innovative approach aims to address critical issues in infusion therapy, including medication errors and cost-effectiveness, ultimately improving patient quality of life. The company markets its products through partnerships in the U.S., Europe, China, and Taiwan, collaborating with notable firms in the pharmaceutical industry. Established in 2003 and based in San Francisco with an additional site in Gent, Belgium, BioQ Pharma was formerly known as BioQuiddity Incorporated until its name change in 2015.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.